Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emilio Bria

Showing results (321-330 of 377) with videos related to

Pageof 38
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 21, 2021
Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune EvasionFabio Conforti, Laura Pala, Eleonora Pagan, et al.
Lung Cancer (Amsterdam, Netherlands)|July 20, 2019
Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trialEnrica Capelletto, Maria Rita Migliorino, Alessandro Morabito, et al.
American Journal of Cancer Research|September 2, 2015
Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplificationMatteo Brunelli, Alessia Nottegar, Giuseppe Bogina, et al.
JAMA Oncology|September 8, 2018
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent ChemotherapyRoberto Ferrara, Laura Mezquita, Matthieu Texier, et al.
Lung Cancer (Amsterdam, Netherlands)|April 5, 2016
BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational studyTiziana Vavalà, Alessandro Follador, Marcello Tiseo, et al.
NPJ Breast Cancer|February 5, 2025
Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapyLuca Mastrantoni, Giovanna Garufi, Giulia Giordano, et al.
JCO Precision Oncology|June 12, 2026
Liquid Biopsy Monitoring in <i>BRAF</i> V600E-Mutated Patients With Non-Small Cell Lung Cancer Treated With Dabrafenib Plus Trametinib: The Prospective, Multicenter LiBRA Study (GOIRC-03-2020)Alessandro Leonetti, Monica Pluchino, Roberta Minari, et al.
Frontiers in Oncology|July 24, 2024
Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: the IMMINENT studyMarco Sposito, Lorenzo Belluomini, Riccardo Nocini, et al.
European Journal of Cancer (Oxford, England : 1990)|August 31, 2022
Detection of ALK fusion variants by RNA-based NGS and clinical outcome correlation in NSCLC patients treated with ALK-TKI sequencesFabrizio Tabbò, Lucia Anna Muscarella, Elisa Gobbini, et al.
Cancer Discovery|July 12, 2020
Disabled Homolog 2 Controls Prometastatic Activity of Tumor-Associated MacrophagesIlaria Marigo, Rosalinda Trovato, Francesca Hofer, et al.
Pageof 38

Showing results (321-330 of 377) with videos related to

Sort By:
Pageof 38
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 21, 2021
Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune EvasionFabio Conforti, Laura Pala, Eleonora Pagan, et al.
Lung Cancer (Amsterdam, Netherlands)|July 20, 2019
Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trialEnrica Capelletto, Maria Rita Migliorino, Alessandro Morabito, et al.
American Journal of Cancer Research|September 2, 2015
Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplificationMatteo Brunelli, Alessia Nottegar, Giuseppe Bogina, et al.
JAMA Oncology|September 8, 2018
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent ChemotherapyRoberto Ferrara, Laura Mezquita, Matthieu Texier, et al.
Lung Cancer (Amsterdam, Netherlands)|April 5, 2016
BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational studyTiziana Vavalà, Alessandro Follador, Marcello Tiseo, et al.
NPJ Breast Cancer|February 5, 2025
Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapyLuca Mastrantoni, Giovanna Garufi, Giulia Giordano, et al.
JCO Precision Oncology|June 12, 2026
Liquid Biopsy Monitoring in <i>BRAF</i> V600E-Mutated Patients With Non-Small Cell Lung Cancer Treated With Dabrafenib Plus Trametinib: The Prospective, Multicenter LiBRA Study (GOIRC-03-2020)Alessandro Leonetti, Monica Pluchino, Roberta Minari, et al.
Frontiers in Oncology|July 24, 2024
Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: the IMMINENT studyMarco Sposito, Lorenzo Belluomini, Riccardo Nocini, et al.
European Journal of Cancer (Oxford, England : 1990)|August 31, 2022
Detection of ALK fusion variants by RNA-based NGS and clinical outcome correlation in NSCLC patients treated with ALK-TKI sequencesFabrizio Tabbò, Lucia Anna Muscarella, Elisa Gobbini, et al.
Cancer Discovery|July 12, 2020
Disabled Homolog 2 Controls Prometastatic Activity of Tumor-Associated MacrophagesIlaria Marigo, Rosalinda Trovato, Francesca Hofer, et al.
Pageof 38